NuCana plc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filer
State of Incorporation
United Kingdom
Business Address
3 LOCHSIDE WAY, EDINBURGH, X0, EH12 9DT
Mailing Address
3 LOCHSIDE WAY, EDINBURGH, X0, EH12 9DT
Phone
44-0-131-357-1111
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | March 24, 2026 | View on SEC |
| 3 Initial insider ownership report | March 20, 2026 | View on SEC |
| 3 Initial insider ownership report | March 19, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| 20-F Foreign company annual report | March 19, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
March 19, 2026
- Advancing proprietary ProTide™ technology for novel anti-cancer treatments.
- Acelarin (NUC-1031) is in a pivotal Phase 3 clinical trial for advanced biliary tract cancer.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.